Novo Nordisk and AI-driven Gensaic enter into $354m cardiometabolic deal
Novo Nordisk has signed a deal with AI-driven protein design company Gensaic to develop tissue-targeted therapies for ...
Gensaic Announces Collaboration with Novo Nordisk to Unlock Next Generation Precision Therapies
Total deal value of up to $354 million in upfront, development, and commercial milestone payments per target plus tiered ...
Le Lézard1d
Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
Revvity, Inc. , today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against ...
Le Lézard1d
MedStar Health Finds 79% of People Polled are Unaware of when to get a Colonoscopy
A national survey conducted by MedStar Health to gauge the public's knowledge of screening guidelines for colorectal cancer, ...
FierceBiotech1d
Novo bets up to $354M per target on Gensaic’s tissue-selective delivery tech
Novo is paying Gensaic up to $354 million per target in upfront fees and development and commercial milestones, plus tiered ...